Status:
COMPLETED
Interest of the Second Phase of the Oral Challenge Test in Patients With Suspected Long-standing Penicillin Allergy
Lead Sponsor:
Fondation Hôpital Saint-Joseph
Conditions:
Allergy Penicillin
Eligibility:
All Genders
18+ years
Brief Summary
The most common drug allergy reported is penicillin allergy, approximately 10% of the world's population. According to the latest studies, only 1-2% of them have a proven hypersensitivity to penicilli...
Eligibility Criteria
Inclusion
- Patient aged ≥ 18 years
- Patient with a history of drug allergy and eviction for more than 12 months of penicillins A: mainly amoxicillin and amoxicillin + clavulanic acid
- Patients who had two amoxicillin or Augmentin Oral Challenge Test between December 2017 and December 2018 in allergology department of the Paris Saint-Joseph hospital
- French-speaking patient
Exclusion
- Patient with uncontrolled asthma
- Patient with an ongoing infection
- Patient with positive skin tests for penicillin before the first TPO
- Patient under guardianship or curatorship
- Patient deprived of liberty
- Patient objecting to participation in the study
Key Trial Info
Start Date :
July 20 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 9 2023
Estimated Enrollment :
195 Patients enrolled
Trial Details
Trial ID
NCT04513938
Start Date
July 20 2020
End Date
January 9 2023
Last Update
April 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Groupe Hospitalier Paris Saint-Joseph
Paris, France, 75014